Cell Line Development2024-05-06T16:21:00-04:00

Cell Line Development.

Characterization for Cell Line Development and Biologics Production.

In the case of antibodies, early characterization is essential in the initial stages of production. Liquid chromatography mass spectrometry (LC-MS) facilitates sensitive and rapid analysis of antibodies, including:

  1. Identity: Conducting high-throughput screening and validation of clone pools.
  2. Purity: Identifying and characterizing protein product variations and contaminants essential for informed cell line engineering.
  3. Composition: Analyzing post-translational modifications (PTMs), glycosylation patterns, and disulfide bond arrangements to determine favourable production conditions.

Services for Cell Line Development.

We support the workflows for cell line development at all stages. Contact us to discover how we can help with your cell line development application.

Antibody Sequencing & Discovery Services.

Peptide Mapping

Antibody verification by real-time peptide mapping. Antibody sequence confirmation service for reproducibility.
Explore Peptide Mapping Service

Glycosylation Analysis

Identify the glycan profile and distribution within the host-expression system to facilitate selection and scaling of production.
Explore Glycan Analysis

Sequence Variant Analysis

Identify single point mutations, amino acid substitutions, and contaminants from recombinantly produced mAbs.
Explore Sequence Variant Analysis

PTM and Disulfide Bond Analysis

Discover PTMs and locations of disulfide bonds to optimize biologics production.

Explore PTM Analysis

Explore Disulfide Bond Analysis

SPR Binding Kinetics

Characterize the binding properties of expressed antibody products to target antigens.

Explore SPR Binding Kinetics

HDX-MS Binding Kinetics

Characterize linear and conformational epitopes for expressed antibody products against target antigens.

Explore HDX-MS Epitope Mapping

“We’re focused on coupling cytokines with a highly engineered VHVL of an antibody. So by sequencing the antibodies with Rapid Novor we are able to pull out the CDR to graft them into our platform and test in vitro and in vivo.”

Pavel Khrimian – Co-founder and CBO, Deka Biosciences

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 9000+ antibodies and we are eager to help you.